Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This study found that the type of reporter significantly influences the detection of cancer therapy-induced alopecia signals, highlighting differences in signal amplification between patients and healthcare professionals.

This study analyzed data from the FDA Adverse Event Reporting System to evaluate cancer therapy–induced alopecia, finding that reporter type significantly affects signal detection, with docetaxel showing the highest disproportionate association overall, and vismodegib ranking highest among healthcare professional reports.

This study investigated the association between hair loss and medications affecting the GH/IGF-1 pathway, using the FDA Adverse Event Reporting System to analyze reporting odds ratios of alopecia.

This study found an association between finasteride use and increased reporting of suicidality and depression in young patients with androgenetic alopecia, potentially mediated by sexual dysfunction.

Finasteride use for hair loss is linked to an increased risk of suicidal thoughts and a higher risk of suicide.

Finasteride, a hair loss drug, is linked to increased suicidal thoughts, particularly when used for hair loss.

The conclusion is that finasteride is linked to an increased risk of suicidal thoughts and a higher risk of completed suicide when used for hair loss.

In this study, the use of finasteride in young patients may be linked to a higher risk of anxiety, depression, and suicide-related adverse events.

This abstract raises concerns about the safety of finasteride, a medication often used for treating hair loss and prostate issues, due to emerging reports linking it to cognitive dysfunction.

This study found that finasteride use was significantly associated with the reporting of obstructive sleep apnea and insomnia compared to all other drugs in the FAERS database.

This study found that finasteride use was significantly associated with reports of obstructive sleep apnea and insomnia compared to other drugs in the FAERS database.

This study examined the FDA Adverse Event Reporting System database and found significant associations between low-dose oral minoxidil use and adverse events like pericardial effusion, highlighting the need for caution and recommending the use of the lowest effective dose until more safety data are available.

This study examined the cardiovascular safety of oral minoxidil, used off-label for androgenetic alopecia, particularly as its usage expands in real-world settings, although specific results were not detailed in the abstract.

This study found that oral minoxidil is associated with a higher proportional reporting of several cardiovascular adverse events compared to topical minoxidil in spontaneous FDA reports, but these signals should be interpreted as hypothesis-generating rather than evidence of clinical safety.

This research review found that spironolactone can significantly improve acne severity more effectively than a placebo, with 73.3% of patients reporting satisfaction despite a 26.7% rate of adverse events among the 1,548 participants studied.

This review discusses the effects of 5ARI drugs on male reproductive parameters, reporting potential decreases in sperm count and motility more significantly in men with pre-existing oligozoospermia, but does not provide fertility outcomes.

This review discusses the impact of weight gain and obesity on the development of polycystic ovary syndrome and explores lifestyle strategies to manage the condition, without reporting new clinical results.

This review discusses the clinical applications and adverse effects of 5-alpha reductase inhibitors for treating benign prostatic hyperplasia and androgenic alopecia, noting controversies around their implications for other diseases, without reporting new results.

This study found a significant association between montelukast and neuropsychiatric adverse events such as suicidal ideation and depression, suggesting that the drug's interaction with specific genes may contribute to these effects.

This study found that digoxin treatment was significantly associated with anemia adverse reactions in patients with atrial fibrillation and heart failure, suggesting a need for caution in its clinical use.

The study by Godfrey et al. highlights a potential link between GLP-1 receptor agonists, specifically semaglutide and tirzepatide, and the risk of alopecia, emphasizing the need for further investigation and patient awareness.

This study found evidence suggesting that hypertrichosis may be an adverse effect of inhaled corticosteroids in children, although it does not always resolve after stopping treatment.

This study confirms an association between TNF-α antagonist exposure and alopecia, indicating a class effect among the medications examined.

This study identified several anticancer drugs, including vinblastine and bortezomib, that significantly increase the risk of developing chemotherapy-induced peripheral neuropathy, with variations in time-to-onset among different drug categories.

In this study, researchers found that sepsis or septic shock significantly increased the risk of patient-reported alopecia in survivors of critical illness.

Finasteride toxicity information is limited, poor quality, and biased.

This study found significant signals of sexual dysfunction associated with finasteride use, particularly in younger patients treated for alopecia, though confounding factors may partly contribute to reported cases.

This study found that finasteride use was associated with significantly higher odds of obstructive sleep apnea and insomnia compared to other medications.

In this study, transverse sectioning of scalp biopsy samples showed higher diagnostic accuracy than vertical sectioning for noncicatricial alopecia, although both techniques are important for accurate diagnosis.